Certara (CERT) TD Cowen 46th Annual Health Care Conference summary

Leadership transition and strategic direction

• New CEO Jon Resnick, in role since January, is shifting from fact-finding to implementing solutions and driving operational excellence.

• Focus is on leveraging a strong team, market-leading products, and fostering innovation to elevate the business.

• Strategic priorities include enhancing management scale, operational rigor, and customer centricity, especially in MIDD and Biosimulation.

• Emphasis on disciplined product management and aligning resources to high-growth areas.

• Plans to improve communication around portfolio strengths and growth engines in coming months.

Platform and product innovation

• Core growth drivers are the MIDD and Biosimulation segments, representing about two-thirds of the business.

• Simcyp remains a central product, with recent major releases aligned to customer needs and industry trends.

• AI integration is advancing, with Phoenix Cloud and Certara IQ (AI-enabled QSP) highlighted as key innovations.

• QSP is the fastest-growing area, and AI investments are expected to impact ARR and sales from late 2024 into 2027.

• Cloud migration for Phoenix and broader AI-enabled offerings are expected to drive Tier 1 customer adoption.

Regulatory services and market positioning

• Ongoing strategic review of the Regulatory services business, balancing market pressure to divest with its profitability and resilience.

• The business has shown resilience against AI-driven commoditization and continues to generate strong bookings.

• Decision on the future of Regulatory services expected within weeks, with focus on maximizing economic value.

• Deep relationships with over 20 global regulators provide a competitive advantage and facilitate client success.

• Regulatory expansion in areas like NAMs, pediatrics, and organ impairment is creating new growth opportunities.